Elaine Shuo Feng
PhD MPH
Statistician/Epidemiologist
Dr Elaine Shuo Feng has joined the Oxford Vaccine Group as a epidemiologist/statistician since September 2019. She is currently working on the correlates of protection of Oxford-AZ vaccine against SARS-CoV-2, and immunogenicity and efficacy of pneumococcal vaccines using network meta-analyses of individual participant data.
Elaine has obtained her BSc in Peking University, and MPH and PhD (under supervision by Prof Benjamin Cowling) in The University of Hong Kong. Her primary research interest is infectious disease epidemiology, in particular understanding immunogenicity, efficacy, effectiveness and impact of vaccines on infectious diseases.
Elaine has been involved in studies estimating the effectiveness of influenza vaccines using the test-negative design. She was participated in test-negative study data analysis in mainland China, Hong Kong and the US. She has also examined methodological issues in this study design including the impact of virus interference. Specifically, she investigated the intraseasonal waning rate of influenza vaccine effectiveness among hospitalised children in Hong Kong. Elaine has also involved in studies estimating influenza-associated disease burden in 30 provinces in China.
Key publications
-
Rational use of face masks in the COVID-19 pandemic
Journal article
Feng S. et al, (2020), The Lancet Respiratory Medicine
-
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article
Feng S. et al, (2021), Nat Med, 27, 2032 - 2040
-
Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study
Journal article
Feng S. et al, (2018), The Lancet Respiratory Medicine, 6, 925 - 934
Recent publications
-
Cost-effectiveness of fractional doses of COVID-19 vaccine boosters in India
Journal article
Du Z. et al, (2023), Med
-
The impact of repeated vaccination on relative influenza vaccine effectiveness among vaccinated adults in the United Kingdom.
Journal article
Lim WW. et al, (2022), Epidemiol Infect, 1 - 30
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2022), Nat Med
-
Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable.
Journal article
Haeusler IL. et al, (2022), Clin Exp Immunol, 209, 188 - 200
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
-
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Journal article
Munro APS. et al, (2022), Lancet Infect Dis
-
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2022), J Infect